Abstract Poster Wall

2022 Kidney Cancer Research Summit

Abstract 27

Evaluation of Growth Rates for Small Renal Masses in Elderly Patients Undergoing Active Surveillance
Ridwan Alam MD, MPH

Abstract 28

Optimal Treatment by Invoking biologic Clusters in Renal Cell Carcinoma (OPTIC RCC): A prospective two arm phase II trial utilizing a novel RNA sequencing-based biomarker to assign treatments
Scott Haake MD

Abstract 32

VHL-mediated ubiquitination of the kinase Mps1 regulates the mitotic checkpoint in clear cell renal cell carcinoma
Mark Woodford PhD

Abstract 33

No Difference in Renal Function Outcomes for Patients with Oncocytoma Managed with Active Surveillance vs. Partial Nephrectomy
Spencer Bell MD

Abstract 34

Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
Scott Haake MD, PhD

Abstract 35

Role of Histology in Influencing Outcomes after Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Pranjal Agrawal MD

Abstract 36

Cytoreductive Nephrectomy with Concomitant IVC Tumor Thrombectomy in Metastatic Renal Cell Carcinoma
Pranjal Agrawal MD

Abstract 42

Vascular endothelial profilin-1 Inhibition suppresses tumor progression in renal cancer
David Gau PhD

Abstract 44

Outcomes of patients with advanced variant histology renal cell carcinoma (RCC) treated with systemic therapy
Danielle Urman

Abstract 45

SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma
Toni Choueiri MD

Abstract 48

Characterization of FH variants in their role in HLRCC-associated kidney cancer
Blake R Wilde PhD

Abstract 50

Pro-survival role of protein phosphatase-5 (PP5) in clear cell renal cell carcinoma through its post translational regulation
Rebecca A Sager MD, PhD

Abstract 51

Investigating germline susceptibility to renal cell carcinoma within the Canadian population
Kate I Glennon BSc

Abstract 54

Evaluating the clinical utility of Circulating Tumor Cells (CTC) profiling to predict selection of preferred therapeutic regimens in Newly Diagnosed or Pretreated Refractory Renal Cell Carcinoma (RCC)
Ulka Vaishampayan MD

Abstract 55

Biomarkers of Disease Burden and Treatment Response in Renal Medullary Carcinoma
Kyle Blum MD, MS

Abstract 57

Induction of mitochondrial metabolic activity and repression of antigen presentation underly progression of localized clear cell renal cell carcinoma
Behrouz Shamsaei PhD

Abstract 58

The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect in renal cancer
Jennifer Heritz

Abstract 61

Belzutifan plus lenvatinib versus cabozantinib after anti–PD-1/PD-L1 treatment in patients with advanced renal cell carcinoma: the randomized, phase 3 LITESPARK-011 study
Daniel YC Heng MD, MPH

Abstract 65

Correlation of serum iron level and duration of response to ipilimumab and nivolumab in metastatic clear cell renal carcinoma (mccRCC)
James Brundage MS

Abstract 66

Clinical and Decision-Making Drivers of Renal Mass Biopsy for Clinical T1 Kidney Tumors
Kathryn Gessner MD, PhD

Abstract 67

Impact of Age on Functional Decline Following Radical Nephrectomy: Analysis of the International Marker Consortium for Renal Cancer (INMARC)
Mimi Nguyen BS

Abstract 68

Comparison of Nephrectomy and Ablation for cT1b Renal Masses
Kerith Wang BA

Abstract 71

Clinical and genomic characteristics of patients with metastatic renal cell carcinoma who developed venous thromboembolism
Nicolas Sayegh MD

Abstract 73

Short-Term Outcomes of Active Surveillance for Small Renal Masses in Patients With End-Stage Renal Disease and Immunosuppression
Zoe Gan MD

Abstract 75

Maturation of overall survival (OS) in TIVO-3 with long-term follow-up
Brian Rini MD

Abstract 76

Gut microbiome metagenomic analysis identifies key functional pathways associated with sarcopenia development in patients with metastatic renal cell carcinoma
Zeynep Zengin MD

Abstract 79

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressively advanced stages of renal cell carcinoma, including brain metastases
David Schoenfeld MD, PhD

Abstract 81

Decisional conflict among patients newly diagnosed with clinical T1 renal masses
Amir Feinberg

Abstract 82

A Comparison of Radiographic and Morphometric Characteristics and Outcomes in T3A Pathologically Upstaged and Non-Upstaged Renal Cell Carcinoma
Saeed Ghassemzadeh

Abstract 84

Multiome single-cell genomics profiling identifies epigenetic, transcriptional, and cellular compositional shifts in clear cell renal cell carcinomas
Lucas Salas MD, PhD, MPH

Abstract 85

Pulmonary and cutaneous manifestations of Birt-Hogg-Dube Syndrome in a large clinical cohort
Brian Cortese BS

Abstract 86

Financial Burden of Kidney Cancer Care: CDC National Health Survey Analysis
Spencer Bell MD

Abstract 87

The Mutational Landscape of Resected Clear Cell Renal Cell Carcinoma with Cystic components
Laura Bukavina MD, MPH

Abstract 88

Renal mass manifestations of the Birt-Hoge-Dube syndrome in a large clinical cohort
David Ostrowski BS

Abstract 90

The role of exercise on the physical and mental health of kidney cancer patients and survivors
Khalid Alkhatib MD, MMSc

Abstract 92

Characteristics and Outcomes of T1a Renal Cell Carcinoma Presenting with Metastasis
Luke Wang MD

Posters: Trials in Progress

Abstract 39

Phase II Trial of Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma
Kevin Zarrabi MD, MS

Abstract 41

TiNivo-2: A Phase 3 Study to Compare Tivozanib Plus Nivolumab to Tivozanib Monotherapy in Patients with RCC Who Have Progressed Following ≤2 Lines of Therapy Including an Immune Checkpoint Inhibitor
Toni Choueiri MD

Abstract 49

A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety. PK, PD and clinical activity in patients with advanced ccRCC
Toni Choueiri MD

Abstract 60

Pembrolizumab plus belzutifan as adjuvant treatment of clear cell renal cell carcinoma: phase 3 LITESPARK-022 study
Toni Choueiri MD

Cabozantinib, Nivolumab and Ipilimumab (CaNI) for advanced Renal Cell Carcinoma with Variant Histology
Bradley A McGregor MD


Kidney Cancer Research Summit

October 6–7, 2022, Philadelphia, PA

Click the image above to download the Abstract Book.
Updated 10.4.22